Here, we hypothesized that oncogenic KRAS would drive aberrant upregulation of CCNA2. To test this, we compared CCNA2 expression levels between wild-type and mutant KRAS or pan-RAS (KRAS, HRAS and NRAS) tumor samples in The Cancer Genome Atlas (TCGA) cohort. This evidence concerns the gene CCNA2 and neoplasm.